🔬 Drug keeps HIV viral suppression high in French study
Dolutegravir-Lamivudine showed high viral suppression rates in a 3-year French real-world study. Researchers monitored 304 participants across 49 centers in France from 2020 to 2024. Nearly 90% of treatment-naive individuals suppressed the virus within 6 months, while 94% of pretreated patients maintained suppression. This indicates strong virological success with a favorable safety profile, showing stable body weight. Future studies need to look at longer-term results in different populations. 🔬